.jpg)
Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges
A concise report featuring insights from the prominent thought leaders of Biologics 2024
Top R&D Stories of 2023
Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
NextGen Therapeutics
Regeneron’s New Bispecific: A Toxic Success?
Regeneron announced that their bispecific odronextamab had the highest recorded complete response rate for follicular lymphoma, but the therapeutic antibody’s safety profile has thrown up several concerns.
Dual-Action Malaria Vaccine Takes the Punch out of the Parasite
A new vaccine duo developed by scientists at George Washington University stops malaria infection and transmission, the double attack needed to eradicate the disease.
Nexelis’s Collaborative Development for Optimal Clinical Assay
November’s webinar, Adaptive Laboratory Environment: Collaboration Across our Development Teams Produces Optimal Clinical Assay, discusses Nexelis’s process in recombinant protein production, optimisation, and characterisation.
Overcoming Vaccine Manufacturing Challenges
Experts from King’s College London, Janssen, and Merck Sharp & Dohme congregate to talk the future of optimised vaccine manufacturing.
Vaccines After COVID: How the Pandemic Has Changed the Vaccination Market
During the pandemic, a layperson couldn't avoid learning about vaccinations. But as the world returns to “normal”, how does this new-found focus on vaccines manifest for regulators, producers, prescribers, and the public?
Vaccines Europe: Presentations You Won’t Want to Miss
Find out about some of Oxford Global’s most highly anticipated presentations happening at our upcoming Vaccines Congress.
Antibody & Protein Engineering
Roche Fail to Follow in Eisai’s Footsteps: Alzheimer’s Drug Flunks Phase III Trials
Roche revealed that they will stop all Alzheimer’s trials after anti-amyloid beta antibody gantenerumab fails Phase III trials.
Antibody & Protein Engineering
Heart-to-Heart or Head-to-Head: Amgen Heart Drug to Challenge Novartis
New data released from Amgen’s phase II study of olpasiran suggests that the drug could fill a niche in the cardiovascular market.
Universal Vaccines & Vaccine Therapeutics
Mark Doherty, Senior Medical Manager at GSK, leads a Discussion Group on leveraging the mechanisms of action in therapeutic vaccine development.
Antibody & Protein Engineering
AbbVie Ditch Phase II Autoimmune Drug
AbbVie announced that they are dropping the ROR? inverse agonist, marking the end of their collaboration with Inventiva
NextGen Therapeutics
Exploring & Developing Various Biotherapeutic Modalities
Galahad Deperalta, Senior Scientist and Innovation Group Leader at Genentech, leads a Discussion Group on the next generation of biotherapeutic development.
3-Dose Hepatitis B Vaccine Offers Full Protection for People with HIV
Phase III clinical trials from the University of Cincinnati have shown seroprotection in 100% of HIV-positive participants after a 3-dose regimen of the HEPLISAV-B vaccine.